Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Adenocarcinoma Metastatic: early-phase trial registry
3 of 6 indexed Pancreatic Adenocarcinoma Metastatic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Pancreatic Adenocarcinoma Metastatic: 6 US clinical trials tracked, 3 recruiting.
Pancreatic Adenocarcinoma Metastatic is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Colin D. Weekes, M.D., PhD, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-adenocarcinoma-metastatic
OPEN 3 | RECR 50% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Pancreatic Adenocarcinoma Metastatic lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Adenocarcinoma Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Adenocarcinoma Metastatic is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pancreatic Adenocarcinoma Metastatic research.
Colin D. Weekes, M.D., PhD accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Adenocarcinoma Metastatic trials plan to enrol fewer than 100 people.
Median target enrolment is 68 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
Pancreatic Adenocarcinoma Metastatic research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Oncomatryx Biopharma S.L.
NCT07377045
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
Abramson Cancer Center at Penn Medicine
NCT06747845
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Colin D. Weekes, M.D., PhD
NCT05077800
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
NCT06076837
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
The Rogosin Institute
NCT01053013
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Adenocarcinoma Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Adenocarcinoma Metastatic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Adenocarcinoma Metastatic page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Pancreatic Adenocarcinoma Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Colin D. Weekes, M.D., PhD sponsors the most Pancreatic Adenocarcinoma Metastatic trials on record, review their full trial history before evaluating a specific study. See Colin D. Weekes, M.D., PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Adenocarcinoma Metastatic condition card totals 6 registered trials; most-linked intervention RENCA macrobeads; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.